Abstract: The present invention is directed to novel amino acid prostaglandin salts and methods of making and using them.

Abstract: The present invention is directed to novel amino acid prostaglandin salts and methods of making and using them.

Abstract: The present invention is directed to novel amino acid prostaglandin salts and methods of making and using them.

Abstract: The present invention provides a method for treating a central nervous system disorder in a mammalian subject, which comprises administering an effective amount of a 11-deoxy-prostaglandin compound to a subject in need thereof. The invention also provide novel 11-deoxy-prostaglandin compound.

Abstract: The present invention relates to a method of translation or inflammatory response blockade by using a compound that binds to eIF4A, which is the 264th amino acid residue, a method of developing an anti-inflammation, anti-cancer or anti-viral agent by screening a compound that binds to eIF4A.

Abstract: A compound comprising a prodrug of a prostaglandin EP4 agonist, wherein said prodrug is an ester, ether, or amide of an amino acid is disclosed herein. Maintenance of the colonic mucosal barrier by method comprising administering a therapeutically effective amount of a prostaglandin EP4 agonist to a colon of a mammal is also disclosed herein. Dosage forms, medicaments, and compositions, related thereto are also disclosed.

Abstract: The invention provides a novel process for the preparation of prostaglandins and analogues thereof, and new crystalline intermediates in the process.

Abstract: The present invention provides a new and effective process for the synthesis of 17-phenyl-18,19,20-trinor-PGF2? and its derivatives, including the anti-glaucoma drugs Bimatoprost and Latanoprost. The benefit of the present invention rises inter alia from the fact that a major intermediate involved in the synthesis of the above compounds may be isolated from a mixture containing also an undesired isomer, by crystallization. In addition, the undesired isomer may be oxidized to give the starting compound, which is then recycled.

Abstract: Disclosed is a process for the preparation of the anti-glaucoma drug Latanoprost, in good yield, in large amounts and with desired purity. Also disclosed are novel intermediates for the above process.

Abstract: Disclosed is a process for the preparation of the anti-glaucoma drug Latanoprost, in good yield, in large amounts and with desired purity. Also disclosed are novel intermediates for the above process.

Abstract: Vasoactive compounds are described for the treatment of erectile dysfunction and impotence. The compounds are reaction products of an anionic or negatively charged vasoactive or erection-inducing component (such as alprostadil) and a cationic or positively charged vasoactive or erection-inducing component (such as prazosin) or a local anesthetic (such as lidocaine). These components are combined as acids and bases to form an organic salt or ionically bonded compound. The compounds have advantageous solubility characteristics and efficacy. A compound of the invention is combined with a pharmaceutical vehicle to form a composition which preferably includes an emulsifier. A local anesthetic and/or androgenic steroids may also be included. Compositions of the invention may also include more than one vasoactive organic salt compound. The composition can be advantageously formulated and administered to allow self-adjusted dosing, while minimizing or preventing overdosing.

Abstract: A method of inhibiting parasitic activity is disclosed in which the biosynthesis, structure and/or function of the glycosyl phosphatidylinositol (GPI) anchor of said parasite may be affected by incorporating into said GPI anchor selected analogs of myristic acid containing various heteroatoms, substituents and unsaturated bonds, including ester-containing analogs, ketocarbonyl-containing analogs, sulfur-containing analogs, double bond- and triple bond-containing analogs, aromatic moiety-containing analogs, nitrated analogs and halogenated analogs.

Abstract: Object: To provide novel prostaglandin E.sub.1 analogues which have more excellent pharmaceutical effects, longer duration of the effects and less side-effects than the prior art prostaglandin E.sub.1 's.Constitution: A PGE.sub.1 analogue represented by the formula: ##STR1## (wherein A is a vinylene group or an ethynylene group, R.sup.1 is a hydrogen atom, an alkyl group having 1 to 6 carbon atoms or an allyl group, R.sup.2 is a branched aliphatic hydrocarbon group having 5 to 10 carbon atoms), or a salt thereof.

Abstract: The invention relates to cyclopentane ether derivatives of Formula I ##STR1## their salts with physiologically compatible bases, as well as the .alpha.-, .beta.- or .gamma.-cyclodextrin clathrates, and also the liposome-encapsulated compounds of Formula I, processes for their production, and their pharmaceutical usage.

Abstract: A botulinum toxin neutralizer comprising at least one fatty acid having the number of carbon atoms of at least 12. Such a fatty acid may be any of saturated fatty acids such as lauric acid, myristic acid, palmitic acid, stearic acid, nonadecanoic acid, arachidic acid, and behenic acid or any of unsaturated fatty acids such as oleic acid. The toxin neutralizer acts as if it were an antagonistic receptor for botulinum toxin and, when encountering botulinum toxin in human body, directly combines with the toxin and disables the toxin from combining with the neuromuscular tissues of human body to prevent the outbreak of botulism. The toxin thus neutralized and affixed to the botulinum toxin neutralizer is excreted from the human body. The botulinum toxin neutralizer can be manufactured easily and economically from a naturally occurring glyceride and is thus far less costly then the known antitoxin of ganglioside GT1b produced from bovine brain.

Abstract: Tris-tetrazoles of formula I, ##STR1## wherein A is alkylene and R is hydrogen, alkyl or phenyl, are suitable blowing agents for thermoplastic resins, especially for polycarbonates and aromatic polyethers. The foaming process can be carried out at a temperature range of 230.degree. to 300.degree. C., the resulting foamed articles have a fine and homogeneous cellular structure.The tris-tetrazoles I can be synthesized from the corresponding tris-nitriles or tris-imidchlorides by reaction with an alkali azide.